Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Slides:

Advertisements

Similar presentations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Advertisements

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 2 Multiscale modelling in oncology

Figure 3 Risk-adapted and response-adapted

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Volume 21, Issue 3, Pages (March 2012)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 3 Drug cycling with collateral sensitivity

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

chemotherapy for patients with MC versus those with AC

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway

Figure 2 Dominance of the cell-extrinsic effects of autophagy

Figure 2 Frequency and overlap of alterations

Figure 2 Variations between planned and delivered doses of radiation

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Volume 21, Issue 3, Pages (March 2012)

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Determination of the primary site

Figure 4 Molecular signalling and immunological

Figure 1 Gene-expression quantification methods

Top, NEPC biology is estimated to drive approximately 25% of the lethal prostate cancers indicated by the blue zone. Top, NEPC biology is estimated to.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Figure 1 Critical signalling pathways involved in PDAC pathogenesis Figure 1 | Critical signalling pathways involved in PDAC pathogenesis. Critical signalling pathways associated with initiation and progression of pancreatic ductal adenocarcinoma (PDAC): from left to right, the Hedgehog (HH), PI3K/AKT, RAS/MAPK, and autophagy pathways. Each of these pathways can be exploited, independently or in combination, to develop unique treatment strategies. The figure highlights several nanomedicine and/or small-molecule agents, either FDA approved or in various stages of preclinical or clinical development, that are being pursued to inhibit and/or interfere with the pathways involved in PDAC, in order to better combat the disease. Adiseshaiah, P. P. et al. (2016) Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.119